Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.64 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.64 |
| ▸ | CETP | P11597 | 6/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11088776 | 0.96 | CYP4F2 (0.69) | CYP4F2CYP4A11CETPNPSR1EPHX1 | |
| SCHEMBL28199817 | 0.94 | CYP4F2 (0.67) | CYP4F2CYP4A11CETPNPSR1NAAA | |
| SCHEMBL3150942 | 0.91 | CYP4F2 (0.72) | CYP4F2CYP4A11CETPNPSR1EPHX1 | |
| SCHEMBL2235513 | 0.89 | CYP4F2 (0.70) | CYP4F2CYP4A11CETPNPSR1EPHX1 | |
| SCHEMBL5271625 | 0.88 | CYP4F2 (0.58) | CYP4F2CYP4A11CETPNPSR1MEN1 | |
| SCHEMBL8468936 | 0.85 | CYP4F2 (0.46) | CYP4F2CYP4A11CETPNAAAMEN1 | |
| SCHEMBL20617478 | 0.84 | CYP4F2 (0.50) | CYP4F2CYP4A11CETPNPSR1EPHX1 | |
| SCHEMBL25742466 | 0.84 | CYP4F2 (0.50) | CYP4F2CYP4A11CETPNPSR1 | |
| SCHEMBL8071102 | 0.83 | CYP4F2 (0.45) | CYP4F2CYP4A11CETPMEN1KMT2A | |
| SCHEMBL11476639 | 0.83 | CYP4F2 (0.90) | CYP4F2CYP4A11CETPNPSR1ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419999-B2 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-09-02 | — | — | US | disclosed |
| EP-1556347-A4 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2006-08-09 | — | — | EP | disclosed |
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-12-29 | — | — | US | disclosed |
| EP-1556347-A2 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2005-07-27 | — | — | EP | disclosed |
| WO-2003103604-A2 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V (AN) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | PGF, HPGDS, PTGIS | CYP4F2 1220/4885CYP4A11 151/4885CETP 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.